The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on ...

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Updated data from RUBY-3 ...

JADE101 is an investigational,potentially best-in-class disease-modifyinganti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, ...

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class ...

BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields ...

The Texas-based company announced on Tuesday that its research collaborators will present preclinical data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

Title: Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the ENLIGHT-LN Registry Presenting Author: Mohammad Kamgar, M ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...

Abstract: Deep neural networks (DNNs) are sensitive to adversarial examples which are generated by corrupting benign examples with imperceptible perturbations, or have significant changes but can ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...